Post Traumatic Stress Disorder Clinical Trial
Official title:
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
Post-traumatic stress disorder (PTSD) is a complex disorder expressed as a variety of neurobiological symptoms, including anxiety, re-experiencing, hyperarousal, and avoidance symptoms, along with comorbidities such as anxiety, depression, and increased risk for self-medicating substance abuse. Currently, there are only two approved medications in the United States (US) for PTSD, paroxetine and sertraline. Psychedelic medications, including psilocybin, have recently received breakthrough designation by the US Food and Drug Administration (FDA) for other psychiatric indications. Although no formal clinical trials have yet investigated psychedelic substances for the treatment of PTSD, the available evidence warrants such an investigation. The present study aims to investigate the effect of psilocybin on treatment-resistant PTSD.
Post-traumatic stress disorder (PTSD) is a complex disorder expressed as a variety of neurobiological symptoms, including anxiety, re-experiencing, hyperarousal, and avoidance symptoms, along with comorbidities such as anxiety, depression, and increased risk for self-medicating substance abuse. Currently, there are only two approved medications in the United States (US) for PTSD, paroxetine and sertraline. These selective serotonin reuptake inhibitors (SSRIs) have limited efficacy. Furthermore, there is a lack of efficacious pharmacotherapy for treatment-resistant PTSD; PTSD remains a chronic and sometimes debilitating condition. New research into other treatment options for PTSD are warranted. Psychedelic medications, including psilocybin, have recently received breakthrough designation by the US Food and Drug Administration (FDA) for other psychiatric indications. Psilocybin has received breakthrough designation for treatment of depression. Research on psilocybin has shown that it facilitates fear extinction in mice and promotes neuroplasticity, increasing neurogenesis, spinogenesis and synaptogenesis. These properties may contribute to antidepressive and anxiolytic effects. Psilocybin also reduces activity in the amygdala during threat responses; decreased amygdala reactivity is correlated with positive mood. This is particularly relevant since individuals with PTSD showed increased reactivity in the amygdala, which may increase the ability to process traumatic memories. Although no formal clinical trials have yet investigated psychedelic substances for the treatment of PTSD, the available evidence warrants such an investigation. The present study aims to investigate the effect of psilocybin on treatment-resistant PTSD. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
| Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
| Recruiting |
NCT05934162 -
Efficacy of Internet-delivered Cognitive-behavior Therapy for PTSD
|
N/A | |
| Recruiting |
NCT05934175 -
Intensive Treatment Versus Standard Weekly Prolonged Exposure for Adults With Post-Traumatic Stress Disorder
|
N/A | |
| Completed |
NCT04460014 -
Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT
|
N/A | |
| Completed |
NCT05877807 -
Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
|
||
| Active, not recruiting |
NCT05992649 -
The Effect of Aquatic Physiotherapy on Veterans Suffering From PTSD - a 40-week Pilotproject
|
N/A | |
| Terminated |
NCT04404712 -
FAAH Availability in Psychiatric Disorders: A PET Study
|
Early Phase 1 | |
| Not yet recruiting |
NCT05331534 -
Effect of Attentional Therapy on Post-traumatic Stress Disorder
|
N/A | |
| Not yet recruiting |
NCT03649607 -
Accelerated Resolution Therapy for HIV Positive African, Caribbean and Black
|
N/A | |
| Not yet recruiting |
NCT04076215 -
Biochemical and Physiological Response to Stressogenic Stimuli
|
N/A | |
| Not yet recruiting |
NCT02545192 -
A Pilot Study of Low Field Magnetic Stimulation in PTSD: Three Daily Treatments
|
Phase 1 | |
| Completed |
NCT02329418 -
Written Document to Assist Family During Decision of Withholding and Withdrawing Life-sustaining Therapies in the Intensive Care Unit
|
N/A | |
| Active, not recruiting |
NCT00978484 -
A Head-to-head Comparison of Virtual Reality Treatment for Post Traumatic Stress Disorder
|
Phase 3 | |
| Completed |
NCT00760734 -
Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post Concussion Syndrome (PCS) and TBI/Post-Traumatic Stress Disorder (PTSD)
|
Phase 1 | |
| Completed |
NCT03278171 -
Early Detection of Patients at Risk of Developing a Post-traumatic Stress Disorder After a Stay in Intensive Care Unit
|
||
| Recruiting |
NCT05874362 -
People Bereaved by Violent Death : Negative Event Biases and Temporal Perception
|
N/A | |
| Terminated |
NCT03898843 -
Assisted Animal Therapy: ReAnimal
|
N/A | |
| Recruiting |
NCT04747379 -
Psychological Effect of Explicit Recall After Sedation (PEERS)
|
||
| Completed |
NCT03248167 -
Cannabidiol as a Treatment for AUD Comorbid With PTSD
|
Phase 1/Phase 2 |